The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia.
about
Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humansBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsMetabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studiesDecreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorderNeurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysisMagnetic resonance spectroscopy and its applications in psychiatry.Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update.Brain proton magnetic resonance spectroscopy of alcohol use disorders.Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology.Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study.Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study.The effects of antipsychotic treatment on cerebral structure and function in schizophrenia.Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection.Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls.Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.The neurotrophic and neuroprotective effects of psychotropic agents.Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study.Proton magnetic resonance spectroscopy in 22q11 deletion syndrome.Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study.Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.Neural mechanisms of genetic risk for impulsivity and violence in humans.Proton magnetic resonance spectroscopy and thought disorder in childhood schizophreniaAssociation of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system.Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophreniaComparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR SpectAdding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.Regional decoupling of N-acetyl-aspartate and glutamate in schizophreniaImaging genomics and response to treatment with antipsychotics in schizophrenia.Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia.Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patientsN-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary studyProton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia.Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine.Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels.(1)H-MRS of hippocampus in patients after first manic episode.Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.
P2860
Q24644184-50C9AE25-4304-4DFC-911B-B02A565A69A7Q26786247-67C0F8FB-FCBB-4EE1-94CE-AE17006470F1Q26865740-23D2BE9F-3570-4834-BBE2-49F1E2F20B06Q28366808-1463E55B-DF65-4E7E-9B66-09D529C0703CQ30565982-69E9D819-7578-4593-88BA-52B56E474699Q30684591-6ACAB00C-BCF0-4F32-B51A-5F289558E5EEQ30686416-31E71190-9802-40DB-9B22-766B02FF2150Q30859378-FBC48EE3-4427-4ABE-B722-B09B558B8665Q30949960-635A8EF1-D81F-46A9-9EAB-81DF73A9BA20Q31001850-873E63E4-866A-4771-BF23-26AE42D0B78DQ31046921-F9F30890-B1ED-430E-9B59-729C206A5D66Q31048306-926A1E18-DA5A-41F1-84C4-5B151E8BD5C0Q31114435-11491D6F-AB54-4B5B-A6E3-9C6AAB0EF86AQ31120604-D1BBD28D-887E-4E7C-B293-7C2B38F9D9DEQ31131189-8F0A2AD7-8281-43CF-A7F8-FF0C0D7A5984Q33288189-17B73863-02E6-40E8-BD03-0D45E547B2DCQ33429548-8CDD105D-FE1F-41DE-A646-E9197CC6D7A1Q33583992-7EFBBBC1-9B93-4B70-A4D3-0682C3E4C855Q33853511-50F3652B-98BA-4BC7-810D-6D260CA8E6FAQ33955280-7D547339-60B0-45A9-995D-0E41855A4511Q33979126-E20EFC85-8803-4F96-81B1-19B6A25532E4Q34193383-CD4028BB-AFA2-437C-9BBD-5D62519F64C6Q34597413-F1AE74E3-4EDD-4C27-AA15-A075799A207FQ35590170-BD097BCD-BBB7-4C83-9818-DEB919F7D4F9Q35723798-9053D18E-5CF5-494E-AE2E-152FE20A2F8AQ35872055-EB3A2242-7DBB-4301-81D8-B24F82B3EE50Q36247410-C0209BA3-E747-4127-B81F-51205AC60B38Q36247426-6A2B558F-3AB6-44B8-85EA-968A37B3C4E1Q36323522-25E67DF7-05A5-489A-99BE-7AB6A288D4B5Q36401916-12528835-9C62-469E-85BA-3635D6A3B5FBQ36577350-402619B6-C77F-483A-AF07-2F2C3E248BC6Q36850555-14E397E5-FF29-44C8-899A-7A2C92A4BF0CQ36972662-D2796534-07A6-484C-BBE7-70CF86BA901CQ37148337-9E692A91-4A7E-4899-8735-BD5C10D0E376Q41869167-6A1ED909-5C51-4EF3-A875-50C649122662Q44045755-0D47D685-56AB-489D-A712-4C4EE6AAB996Q44407146-8A4556B8-0998-48A6-A45D-979CD1AA2ED6Q46678012-56312E18-52B6-4749-AAEC-9A7177B5CE9BQ49106947-3EFE559B-6C32-4460-85D5-507B54DC5306Q52591935-9F3B86D7-4D3D-431C-B13A-8BD0B85EDADD
P2860
The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The effect of treatment with a ...... n patients with schizophrenia.
@ast
The effect of treatment with a ...... n patients with schizophrenia.
@en
type
label
The effect of treatment with a ...... n patients with schizophrenia.
@ast
The effect of treatment with a ...... n patients with schizophrenia.
@en
prefLabel
The effect of treatment with a ...... n patients with schizophrenia.
@ast
The effect of treatment with a ...... n patients with schizophrenia.
@en
P2093
P1476
The effect of treatment with a ...... n patients with schizophrenia.
@en
P2093
Bertolino A
Callicott JH
Weidenhammer KM
P356
10.1016/S0006-3223(00)00997-5
P407
P577
2001-01-01T00:00:00Z